STIMATE-MUSTN1 readthrough fusion protein (STIMATE-MUSTN1)

STIMATE-MUSTN1 fusion gene arises from a read-through event joining TMEM110 (a transmembrane protein possibly involved in signal transduction at the ER membrane) and MUSTN1 (a nuclear factor implicated in skeletal muscle and chondrocyte differentiation)[2][4][5]. The fusion transcript and resulting protein possess coding potential and have been cataloged in genome databases as naturally occurring in humans, with reported associations to various genome-wide association study (GWAS) traits. Fusion proteins of this type are of emerging interest in cancer biology for their potential as neoantigen targets for immunotherapies such as CAR-T cell therapy, although specific clinical targeting and safety profiles for STIMATE-MUSTN1 remain underexplored[6]. Because this fusion is not widely characterized in terms of specific drug interaction, mechanism, or disease role beyond GWAS associations and cancer fusion cataloguing, entries for interacting drugs, mechanisms, biomarkers, and safety should be considered preliminary or inferred from fusion protein therapeutic trends in oncology.

Other names

TMEM110-MUSTN1TMEM110-MUSTN1 fusion proteinTMEM110-MUSTN1 read-through transcriptTMEM110-MUSTN1 readthroughSTIMATE-MUSTN1

Fusion neoantigen presentation: possible immunogenic epitopes for neoantigen-targeted therapies, such as CAR-T or TCR therapies directed against fusion-specific peptide sequences